Core Insights - MiMedx reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, but down from $0.07 per share a year ago [1] - The company generated revenues of $88.21 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.56% and up from $84.71 million year-over-year [2] - MiMedx shares have declined approximately 28.1% year-to-date, contrasting with the S&P 500's decline of 5.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $93.5 million, and for the current fiscal year, it is $0.29 on revenues of $375 million [7] - The estimate revisions trend for MiMedx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which MiMedx belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.56 per share, reflecting a significant year-over-year decline of 250% [9]

The market expects Alnylam Pharmaceuticals (ALNY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...